Novartis Investigative Site

Saitama 362-0806

1 studies enrolling now · 11 studies all time

What they study most

Breast Cancer, Chronic Myelogenous Leukemia, Heart Failure, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive, Myelogenous Leukemia, Chronic, Neoplasms, Breast, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pediatric Heart Failure, Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

Studies at this site

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP — Recruiting now
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF — Completed
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer — Completed
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure — Completed
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. — Completed
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Completed
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer — Completed
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy — Stopped early